XATRAL 10 Milligram Tablet Prolonged Release
Страна: Ирландия
Язык: английский
Источник: HPRA (Health Products Regulatory Authority)
Характеристики продукта
(SPC)
26-05-2024
Некоторые документы для этого продукта в настоящее время недоступны, вы можете отправить запрос в нашу службу поддержки, и мы сообщим вам, как только мы сможем их получить.
Послать запрос.
Послать запрос.
Активный ингредиент:
ALFUZOSIN HYDROCHLORIDE
Доступна с:
Chemilines Healthcare (Ireland) Limited
код АТС:
G04CA01
ИНН (Международная Имя):
ALFUZOSIN HYDROCHLORIDE
дозировка:
10 Milligram
Фармацевтическая форма:
Tablet Prolonged Release
Тип рецепта:
Product subject to prescription which may be renewed (B)
Терапевтические области:
Alpha-adrenoreceptor antagonists
Статус Авторизация:
Authorised
Дата Авторизация:
2013-08-02
Характеристики продукта
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Xatral 10mg Prolonged Release Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 10mg alfuzosin hydrochloride
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet, prolonged release.
_Product imported from France and Italy:_
Round biconvex three layer tablet; one white layer between two yellow layers.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Treatment of the functional symptoms of benign prostatic hypertrophy.
Adjunctive therapy with urethral catheterisation for Acute Urinary Retention related to BPH.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Xatral 10mg Prolonged Release Tablets are for oral administration.
Xatral 10mg Prolonged Release Tablets should be swallowed whole.
BPH: The recommended dose is one 10mg tablet once daily to be taken after a meal.
AUR: One 10mg tablet daily after a meal to be taken from the first day of catheterisation.
Paediatric population:
Efficacy of Xatral has not been demonstrated in children aged 2 to 16 years (see section 5.1). Therefore, Xatral is not
indicated for use in paediatric population.
4.3 CONTRAINDICATIONS
Hypersensitivity to alfuzosin or any component. History of orthostatic hypotension. Combination with other -
blockers. Hepatic insufficiency.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
As with all alpha
1
-blockers in some subjects, in particular patients receiving antihypertensive medications or nitrates.
In some subjects postural hypotension may develop, with or without symptoms (dizziness, fatigue, sweating) within a
few hours following administration. These effects are usually transient, occur at the beginning of treatment and do not
usually prevent the continuation of treatment. In such cases, the patient should lie d
Прочитать полный документ
